Drug Trial Radar · NCT04275518
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
102
Planned (sponsor's estimate)
Start
Jul 6, 2020
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Yasheng Pharmaceutical Co., Ltd.
- First posted
- Feb 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation. APG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein and shows potent cell growth inhibitory activity in vitro with low nanomolar potencies in a subset of human cancer cell lines. APG-115 has demonstrated its strong antitumor activities with either daily or less frequent dosing-schedules in the acute leukemia xenograft models. This is a phase 1b, open-label, three-stages study that will initially evaluate the safety and PK/PD profile of APG-115 as a single agent, followed by a combination of APG-115 + azacytidine or cytarabine in R/R AML or MDS subjects. Patients will continue treatment for maximally 6 cycles or until progression of disease or unacceptable toxicity is observed or administrative discontinuation whichever occurs first. Patients who continue to be benefit after 6 cycles' treatment will receive additional cycles of treatment until progression of disease, unacceptable toxicity is observed or administrative discontinuation. (As long as it is proven safe).
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
Interventions
APG-115Drug
APG-115 orally once daily from Days 1 to 7 every 28 days.
AzacitidineDrug
75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
CytarabineDrug
1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: From day 1 to the end of cycle 1 (each cycle is 28 days).
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
The First Hospital of Peking University
Beijing, Beijing Municipality, China · Not yet recruiting
Guangzhou panyu central hospital
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Henan Provincial Oncology Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
The First Affilated Hospital of Ganzhou Medical University
Suzhou, Jiangsu, China · Not yet recruiting
The First affiliated hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shanghai Jiao Tong University school of medicine Ruijing Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Sixth people's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.